2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.
Javier Martin-Broto, MD, PhD, medical oncologist, the University Hospital, leader, Villalba General Hospital, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.
It is difficult to make arguments for or against MDM2 inhibitors currently under investigation in phase 3 trials for patients with sarcoma, Martin-Broto says. The first MDM2 agonist to release positive information is milademetan, which is being evaluated vs trabectedin in the phase 3 MANTRA trial (NCT04979442) in patients with dedifferentiated liposarcoma, Martin-Broto explains. Other MDM2 agonists, including BI 907828, are being explored, Martin-Broto continues. The phase 2/3 Brightline-1 trial (NCT05218499) is exploring BI 907828 vs doxorubicin in patients with dedifferentiated liposarcoma.
It may eventually be beneficial to evaluate MDM2 agonists in head-to-head comparative clinical trials, Martin-Broto adds. These agents all carry different affinity and safety profiles, and it remains too early to draw a conclusion as to which could provide the most benefit for patients, Martin-Broto concludes.